Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Has Consensus Price Target of $52.83 According to Analysts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $52.83.

EWTX has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. The Goldman Sachs Group boosted their price target on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. William Blair began coverage on shares of Edgewise Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Raymond James Financial reaffirmed an “underperform” rating and issued a $85.00 price target on shares of Edgewise Therapeutics in a report on Thursday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Thursday, October 15th.

View Our Latest Analysis on Edgewise Therapeutics

Insider Activity

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 854 shares of the company’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $45.48, for a total value of $38,839.92. Following the transaction, the chief marketing officer directly owned 8,139 shares in the company, valued at $370,161.72. This represents a 9.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Nofi sold 4,442 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $45.43, for a total value of $201,800.06. Following the completion of the sale, the chief financial officer directly owned 6,495 shares in the company, valued at approximately $295,067.85. The trade was a 40.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 21.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Edgewise Therapeutics in the second quarter worth $268,415,000. Jupiter Topco LLC bought a new position in Edgewise Therapeutics in the second quarter valued at $246,945,000. Janus Henderson Group PLC increased its stake in Edgewise Therapeutics by 29.5% in the first quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock valued at $186,289,000 after acquiring an additional 1,348,706 shares during the last quarter. Bank of America Corp DE purchased a new stake in Edgewise Therapeutics during the second quarter valued at about $63,312,000. Finally, Marshall Wace LLP raised its position in Edgewise Therapeutics by 20,477.5% during the third quarter. Marshall Wace LLP now owns 1,255,226 shares of the company’s stock valued at $50,962,000 after purchasing an additional 1,249,126 shares in the last quarter.

Edgewise Therapeutics Trading Down 0.6%

Shares of Edgewise Therapeutics stock opened at $41.13 on Tuesday. Edgewise Therapeutics has a 12-month low of $19.76 and a 12-month high of $48.78. The company has a market cap of $4.50 billion, a price-to-earnings ratio of 5.02 and a beta of 0.39. The company’s 50-day moving average price is $41.23 and its 200-day moving average price is $37.26.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $10.18. On average, sell-side analysts predict that Edgewise Therapeutics will post 9.11 earnings per share for the current year.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.

See Also

Analyst Recommendations for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.